Sage Group, a UK-based financial advisory powerhouse, has announced a strategic foray into China’s burgeoning healthcare market through a partnership with Shenzhen’s Cenponts Healthcare, a boutique investment bank with a global outlook. This alliance is set to bridge the gap, offering financial advisory services to Chinese life sciences firms aspiring to commercialize their assets in Western markets, particularly in the US and EU. Concurrently, Sage aims to assist Western companies in securing Chinese partnerships for asset licensing and divestment opportunities.
Established in 2004, Sage Group has expanded its footprint across the US, Europe, Japan, Israel, India, and now China, solidifying its position as a global financial advisory and consulting services provider for life sciences deal-making. The group’s expertise was notably instrumental in facilitating the 2023 deal between GSK and Zhimeng Biopharma Inc., which saw GSK secure ex-China rights to a promising hepatitis B candidate for global development.
Cenponts Healthcare, founded in 2015, specializes in cross-border financing and strategic partnerships within the healthcare sector, with a keen operational focus on China and Europe. The company’s core competencies include equity financing, mergers and acquisitions, license transactions, and business consulting, making it an ideal partner for Sage Group’s expansion plans. – Flcube.com
